Citations

Showing 10 of 108152 citations.

Gut microbiome is associated with multiple sclerosis activity in children
Horton, Mary , McCauley, Kathryn , Fadrosh, Douglas, Fujimura, Kei E. , Ness, Jayne , Wheeler, Yolanda , Gorman, Mark , Rodriguez, Moses , Tillema, Jan‐Mendelt , Belman, Anita , Mar, Soe , Casper, T. Charles , Rose, John , Hart, Janace, Shao, Xiaorong, Barcellos, Lisa F. , Horton, Mary K , Chitnis, Tanuja , Tremlett, Helen , Waubant, Emmanuelle L. , Rodriguez, Moses , Graves, Jennifer , Benson, Leslie , Weinstock‐Guttman, Bianca , Waldman, Amy , Krupp, Lauren , Rensel, Mary R. , Lynch, Susan V.

Mayo Clinic

Annals of Clinical and Translational Neurology | August 19, 2021 | Volume: 8 | Issue: 9 | Pages: 1867-1883

10.1002/acn3.51441 | PMID 34409759 Get It

Abstract Objective To identify features of the gut microbiome associated with multiple sclerosis activity over time. Methods We used 16S ribosomal RNA sequencing from stool of 55 recently diagnosed pediatric‐onset multiple sclerosis patients. Microbiome features included the abundance of individual microbes and networks identified from weighted genetic correlation network analyses. Prentice‐Williams‐Peterson Cox proportional hazards models estimated the associations between features and three disease activity outcomes: clinical relapses and both new/enlarging T2 lesions and new gadolinium‐enhancing lesions on brain MRI. Analyses were adjusted for age, sex, and disease‐modifying therapies. Results Participants were followed, on average, 2.1 years. Five microbes were nominally associated with all three disease activity outcomes after multiple testing correction. These included butyrate producers Odoribacter (relapse hazard ratio = 0.46, 95% confidence interval: 0.24, 0.88) and Butyricicoccus (relapse hazard ratio = 0.49, 95% confidence interval: 0.28, 0.88). Two networks of co‐occurring gut microbes were significantly associated with a higher hazard of both MRI outcomes (gadolinium‐enhancing lesion hazard ratios (95% confidence intervals) for Modules 32 and 33 were 1.29 (1.08, 1.54) and 1.42 (1.18, 1.71), respectively; T2 lesion hazard ratios (95% confidence intervals) for Modules 32 and 33 were 1.34 (1.15, 1.56) and 1.41 (1.21, 1.64), respectively). Metagenomic predictions of these networks demonstrated enrichment for amino acid biosynthesis pathways. Interpretation Both individual and networks of gut microbes were associated with longitudinal multiple sclerosis activity. Known functions and metagenomic predictions of these microbes suggest the important role of butyrate and amino acid biosynthesis pathways. This provides strong support for future development of personalized microbiome interventions to modify multiple sclerosis disease activity.
Differences in management and treatment of traumatic adult pan brachial plexus injuries: a global perspective regarding continental variations
Shin, Alexander Y. , Desai, Ketan, Fox, Michael , Spinner, Robert J. , Shin, Alexander Y , Socolovsky, Mariano , Wang, Shufeng

Mayo Clinic

Journal of Hand Surgery (European Volume) | August 19, 2021 | Volume: 47 | Issue: 1 | Pages: 40-51

10.1177/17531934211039677 | PMID 34407694 Get It

An expert opinion study was designed to query five countries and six brachial plexus surgeons regarding the demographics, mechanisms of injury, evaluation, timing of surgery, reconstructive strategies and controversies in adult traumatic pan brachial plexus injuries. Variations in assessing outcomes, management of neuropathic pain and future considerations were elucidated. Clear differences in regional demographics, mechanisms of injury, patient evaluation and treatment strategies were identified. The role of phrenic nerve and contralateral C7 transfer, acute use of free functioning muscle transfers, root reimplantation and amputation/myoelectric prosthetic fitting were regional/surgeon dependent. Comparison of outcomes across regions requires an understanding of the regional nuances of patient demographics, injury mechanisms, preferred reconstructive strategies and how outcomes are measured. Future studies are required to allow accurate regional comparisons.
Skin concerns in patients with trisomy 21 (Down syndrome): A Mayo Clinic 22‐year retrospective review
Wentworth, Ashley B., Hand, Jennifer L. , Davis, Dawn Marie R. , Tollefson, Megha M. , Davis, Dawn M R

Mayo Clinic

Pediatric Dermatology | August 19, 2021 | Volume: 38 | Issue: S2 | Pages: 73-78

10.1111/pde.14764 | PMID 34409638 Get It

AbstractBackground/ObjectivesTrisomy 21 has known associated clinical phenotypes, including skin and soft tissue concerns. However, the overall prevalence and types of findings are largely unclear.MethodsA retrospective review of children with trisomy 21 and one or more dermatologic diagnoses, seen from 1/1/1994 to 7/1/2016, was performed to record dermatologic diagnoses. If one or more diagnoses were confirmed, further data were collected, including demographics, medical specialty, referrals to dermatology, treatment, complications, and follow‐up.ResultsOne hundred and seventy‐four patients with a diagnosis of trisomy 21 aged 18 years or younger were confirmed to have one or more dermatologic diagnoses. In a total of 479 dermatologic diagnoses, superficial mycoses (12%), skin and soft tissue infections (10%), dermatitis (8%), and folliculitis (8%) were most common. Diagnoses were most commonly made as an outpatient (91%) and by general pediatrics (45%) or dermatology (25%). A significant difference (P < .05) in the frequency of various diagnoses made by different specialties was observed. A significant difference (P < .05) in the treatments recommended by different specialties was also observed. Referrals to dermatology were infrequent (6%). However, a frequent change in diagnosis (61%) or treatment (68%) for patients referred to dermatology was observed.ConclusionsChildren with trisomy 21 are most commonly diagnosed with superficial mycoses, skin and soft tissue infections, dermatitis, and folliculitis. The majority of diagnoses were made by general pediatricians and although dermatology referral was rarely necessary, consultations often resulted in change of diagnosis and/or treatment, supporting consideration of early and frequent dermatology referral.
Reduction in migraine pain intensity in patients treated with erenumab: A post hoc analysis of two pivotal randomized studies
Kudrow, David, Reuter, Uwe , Tenenbaum, Nadia, Lima, Gabriel Paiva da Silva , Chou, Denise E. , Mikol, Daniel D., Reuter, Uwe , Lima, Gabriel Paiva da Silva , Lipton, Richard B. , Dodick, David W. , Zhang, Feng

Mayo Clinic

Cephalalgia | August 19, 2021 | Volume: 41 | Issue: 14 | Pages: 1458-1466

10.1177/03331024211028966 | PMID 34407654 Get It

Background Erenumab (erenumab-aooe in the US) effectively reduces monthly migraine days in episodic and chronic migraine. This traditional outcome does not capture the intensity of headache pain on days with migraine. Methods This post hoc analysis of two pivotal randomized, placebo-controlled studies in patients with episodic migraine and chronic migraine examined the effect of erenumab 70 and 140 mg on migraine pain. Cumulative monthly migraine pain intensity is the sum of the peak pain intensity scores (0 = no migraine to 3 = migraine day with severe pain) on migraine days. Change from baseline in cumulative monthly migraine pain and average monthly pain intensity was assessed over months 4 to 6 for episodic migraine and month 3 for chronic migraine; change in average monthly pain intensity was assessed among monthly migraine days responders/non-responders. Results Efficacy analysis included 946 patients for the episodic migraine study and 656 patients for the chronic migraine study. Cumulative monthly migraine pain decreased significantly with erenumab versus placebo ( p < 0.001, for episodic migraine and chronic migraine). In addition, monthly average migraine pain intensity decreased significantly with erenumab versus placebo for episodic migraine ( p < 0.01); decreases were non-significant for chronic migraine. In comparison with placebo-treated patients, a greater proportion of erenumab-treated patients were pain intensity responders regardless of threshold used. Episodic migraine and chronic migraine patients with a ≥50% reduction in monthly migraine days (responders) had a greater reduction in monthly average pain intensity than non-responders. Conclusions Erenumab reduced cumulative monthly migraine pain in episodic migraine and chronic migraine patients and significantly reduced monthly average migraine pain in episodic migraine, demonstrating treatment benefit beyond reduction in migraine frequency. Clinical Trial Registration: ClinicalTrials.gov, NCT02456740; ClinicalTrials.gov, NCT02066415
Measurable residual disease does not preclude prolonged progression-free survival in CLL treated with ibrutinib
Wang, Victoria , Hanson, Curtis A. , Tschumper, Renee C. , Lesnick, Connie , Braggio, Esteban , Paietta, Elisabeth , Leis, José F., Zhang, Cong Christine, Coutré, Steven , Cashen, Amanda F. , Mato, Anthony R. , Singh, Avina K., Mullane, Michael P., Stone, Richard M. , Litzow, Mark R. , Tallman, Martin S. , Shanafelt, Tait D. , Lesnick, Connie E, Leis, Jose Francisco, Barr, Paul M , Erba, Harry Paul , Litzow, Mark R. , Kay, Neil E , Shanafelt, Tait D , Braggio, Esteban , O’Brien, Susan , Barrientos, Jacqueline C. , Barr, Paul M. , Kay, Neil E.

Mayo Clinic

Blood | August 18, 2021 | Volume: 138 | Issue: 26 | Pages: 2810-2827

10.1182/blood.2020010146 | PMID 34407545 Get It

Abstract E1912 was a randomized phase 3 trial comparing indefinite ibrutinib plus 6 cycles of rituximab (IR) to 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR) in untreated younger patients with CLL. We describe measurable residual disease (MRD) levels in E1912 over time and correlate them with clinical outcome. Undetectable MRD rates (&lt;1 CLL cell per 104 leukocytes) were 29.1%, 30.3%, 23.4%, and 8.6% at 3, 12, 24, and 36 months for FCR, and significantly lower at 7.9%, 4.2%, and 3.7% at 12, 24, and 36 months for IR, respectively. Undetectable MRD at 3, 12, 24, and 36 months was associated with longer progression-free survival (PFS) in the FCR arm, with hazard ratios (MRD detectable/MRD undetectable) of 4.29 (95% confidence interval [CI], 1.89-9.71), 3.91 (95% CI, 1.39-11.03), 14.12 (95% CI, 1.78-111.73), and not estimable (no events among those with undetectable MRD), respectively. In the IR arm, patients with detectable MRD did not have significantly worse PFS compared with those in whom MRD was undetectable; however, PFS was longer in those with MRD levels &lt;10−1 than in those with MRD levels above this threshold. Our observations provide additional support for the use of MRD as a surrogate end point for PFS in patients receiving FCR. In patients on indefinite ibrutinib-based therapy, PFS did not differ significantly by undetectable MRD status, whereas those with MRD &lt;10−1 tended to have longer PFS, although continuation of ibrutinib would very likely be necessary to maintain treatment efficacy.
A significant association between C5 nerve sheath tumors and new postoperative weakness
Mikula, Anthony L. , Lakomkin, Nikita , Jack, Megan M. , Bydon, Mohamad , Spinner, Robert J. , Doan, Matthew K. , Smith, Brandon W.

Mayo Clinic

Journal of Neurosurgery: Spine | August 18, 2021 | Volume: 35 | Issue: 5 | Pages: 638-643

10.3171/2021.2.spine202139 | PMID 34359025 Get It

OBJECTIVE The objective of this study was to determine if patients with nerve sheath tumors affecting the C5 spinal nerve are at greater risk for postoperative weakness than those with similar tumors affecting other spinal nerves contributing to the brachial plexus. METHODS A retrospective chart review (1998–2020)identified patients with pathologically confirmed schwannomas or neurofibromas from the C5 to T1 nerves. Patients with plexiform nerve sheath tumors, tumors involving more than 1 nerve, and malignant peripheral nerve sheath tumors were excluded. Collected variables included basic demographics, tumor dimensions, its location relative to the dura, involved nerve level, surgical approach, extent of resection, presenting symptoms, postoperative neurological deficits, and recurrence rate. RESULTS Forty-six patients (23 men, 23 women) were identified for inclusion in the study with an average age of 47 ± 17 years, BMI of 28 ± 5 kg/m2, and follow-up of 32 ± 45 months. Thirty-nine patients (85%) had schwannomas and 7 (15%) had neurofibromas. Tumors involved the C5 (n = 12), C6 (n = 11), C7 (n = 14), C8 (n = 6), and T1 (n = 3) nerves. Multivariable logistic regression analysis with an area under the curve of 0.85 demonstrated C5 tumor level as an independent predictor of new postoperative weakness (odds ratio 7.4, p = 0.028). Of those patients with new postoperative weakness, 75% improved and 50% experienced complete resolution of their motor deficits. CONCLUSIONS Patients with C5 nerve sheath tumor resections are at higher odds of new postoperative weakness. This may be due to the predominant single innervation of shoulder muscle targets in contrast to other upper extremity muscles that receive input from 2 or more spinal nerves. These findings are important for clinical decision-making and preoperative patient counseling.
SARS-CoV-2 Serologic Assays Dependent on Dual-Antigen Binding Demonstrate Diverging Kinetics Relative to Other Antibody Detection Methods
Theel, Elitza S. , Gorsh, Amy P., Granger, Dane, Roforth, Matthew M., Jerde, Calvin R. , Lasho, Michael A., Andersen, Kylie J. , Murphy, Brenna M., Harring, Julie, Lake, Douglas F. , Svarovsky, Sergei, Senefeld, Jonathon W. , Carter, Rickey E. , Joyner, Michael J. , Baumann, N, Mills, John R. , Kunze, Katie L. , Wu, Liang, Lasho, Michael, Baumann, Nikola A, Carter, Rickey E , Andersen, Kylie , Joyner, Michael J , Senefeld, Jonathon W , Johnson, Patrick W. , Wu, Liang Li

Mayo Clinic

Journal of Clinical Microbiology | August 18, 2021 | Volume: 59 | Issue: 9 | Pages: No page available

10.1128/jcm.01231-21 | PMID 34166066 Get It

Longitudinal studies assessing durability of the anti-severe acute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) humoral immune response have generated conflicting results. This has been proposed to be due to differences in patient populations, the lack of standardized methodologies, and the use of assays that measure distinct aspects of the humoral response.
The Value of Targeted Ultrasound for the Primary Evaluation of Breast Symptoms in Pregnant Women of All Ages
Holtz, Jamie N., Woodard, Genevieve A. , Hayward, Jessica H. , Ray, Kimberly M. , Kannan, Neeta, Joe, Bonnie N. , Lee, Amie Y. , Lee, Amie Y , Greenwood, Heather

Mayo Clinic

Journal of Breast Imaging | August 18, 2021 | Volume: 3 | Issue: 5 | Pages: 556-563

10.1093/jbi/wbab058 | PMID 38424949 Get It

Abstract Objective Data on breast imaging in symptomatic pregnant women are limited. Our aim was to assess the value of targeted breast US for the primary evaluation of breast symptoms in pregnant women of all ages. Methods This IRB-approved retrospective study included all pregnant patients who underwent targeted US for focal breast symptoms at an academic imaging facility over an 18-year period (2000–2018). Clinical, imaging, and pathology results were reviewed. Malignant outcomes were determined by histology. Benign outcomes were confirmed by pathology or ≥2 years of follow-up. Descriptive statistics and 2 × 2 contingency table analyses were performed at the presentation level. Results The study cohort comprised 178 presentations in 175 pregnant women. Mean age was 34.7 years (standard deviation, 5.2). The majority (153/178, 86.0%) were more than 30 years old. At presentation, 42.1% (75/178) were in the first trimester of pregnancy, 27.0% (48/178) in the second, and 29.8% (53/178) in the third. The most common presenting symptom was a palpable lump (162/178, 91.0%), followed by focal pain (7/178, 3.9%). The vast majority (174/178, 97.8%) of cases were non-malignant. However, targeted US detected all 4 malignancies (cancer detection rate, 22/1000; negative predictive value 136/136, 100%). Sensitivity and specificity were 100% (4/4) and 78.2% (136/174), respectively. Conclusion Benign causes of symptoms in pregnant women were far more common; malignancy was rare, accounting for only 2.2% (4/178) of cases. Targeted breast US detected all malignancies, supporting US as the primary imaging modality for evaluating symptomatic pregnant women, regardless of age.
The More the Better? Optimal Aspirin Dosing in Patients With Atherosclerotic Disease
Houghton, Damon E.

Mayo Clinic

The Hematologist | August 18, 2021 | Volume: 18 | Issue: 5 | Pages: No page available

10.1182/hem.v18.5.202152 Get It

Photodynamic priming with triple‐receptor targeted nanoconjugates that trigger T cell‐mediated immune responses in a 3D in vitro heterocellular model of pancreatic cancer
Silva, Pushpamali De , Bano, Shazia , Wang, Kenneth K. , Maytin, Edward V. , Hasan, Tayyaba , De Silva, Pushpamali , Hasan, Tayyaba , Pogue, Brian W.

Mayo Clinic

Nanophotonics | August 18, 2021 | Volume: 10 | Issue: 12 | Pages: 3199-3214

10.1515/nanoph-2021-0304 | PMID 37485044 Get It

Abstract Photodynamic priming ( PDP ), a collateral effect of photodynamic therapy, can transiently alter the tumor microenvironment (TME) beyond the cytotoxic zone. Studies have demonstrated that PDP increases tumor permeability and modulates immune‐stimulatory effects by inducing immunogenic cell death, via the release of damage‐associated molecular patterns and tumor‐associated antigens. Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of cancers with a stubborn immunosuppressive TME and a dense stroma, representing a challenge for current molecular targeted therapies often involving macromolecules. We, therefore, tested the hypothesis that PDP’s TME modulation will enable targeted therapy and result in immune stimulation. Using triple‐receptor‐targeted photoimmuno‐nanoconjugate (TR‐PINs)‐mediated PDP , targeting epidermal growth factor receptor, transferrin receptor, and human epidermal growth factor receptor 2 we show light dose‐dependent TR‐PINs mediated cytotoxicity in human PDAC cells (MIA PaCa‐2), co‐cultured with human pancreatic cancer‐associated fibroblasts (PCAFs) in spheroids. Furthermore, TR‐PINs induced the expression of heat shock proteins (Hsp60, Hsp70), Calreticulin, and high mobility group box 1 in a light dose and time‐dependent manner. TR‐PINs‐mediated T cell activation was observed in co‐cultures of immune cells with the MIA PaCa‐2‐PCAF spheroids. Both CD4 + T and CD8 + T cells showed light dose and time‐dependant antitumor reactivity by upregulating degranulation marker CD107a and interferon‐gamma post‐PDP. Substantial tumor cell death in immune cell‐spheroid co‐cultures by day 3 shows the augmentation by antitumor T cell activation and their ability to recognize tumors for a light dose‐dependent kill. These data confirm enhanced destruction of heterogeneous pancreatic spheroids mediated by PDP ‐induced phototoxicity, TME modulation and increased immunogenicity with targeted nanoconstructs.